NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

ABSTRACT: The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: * Safety and tolerability of NT-I7 in combination with pembrolizumab * Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory (R/R) tumors. The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R ovarian cancer (OC).

DISEASE(S): Solid Tumor,Carcinoma,Triple Negative Breast Neoplasms,Small Cell Lung Cancer,Small Cell Lung Carcinoma,Non Small Cell Lung Cancer,Triple Negative Breast Cancer,Pancreatic Cancer,Lung Neoplasms,Neoplasms,Ovarian Cancer,Any Advanced Solid Tumors,Microsatellite Stable Colorectal Cancer,Cancer

PROVIDER: 2334955 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR